gluconic acid has been researched along with Cancer of Head in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baltzer, L; Brandwein, HJ; Franco, JL; Freeman, SM; Hadden, JW; Kenady, DE; Roth, Z | 1 |
| Baltzer, L; Brandwein, HJ; Carroll, WR; Dolan, RW; Fee, WE; Freeman, SM; Gillespie, MB; Hadden, JW; Kaplan, MJ; Kenady, DE; Kirkley, TD; Moyer, JS; Newman, JG; Spring, PM; Suen, J; Wolf, GT | 1 |
2 trial(s) available for gluconic acid and Cancer of Head
| Article | Year |
|---|---|
A phase 1 safety study of an IRX-2 regimen in patients with squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cyclophosphamide; Cytokines; Drug Administration Schedule; Female; Gluconates; Head and Neck Neoplasms; Humans; Immunotherapy; Indomethacin; Intention to Treat Analysis; Male; Middle Aged; Safety | 2011 |
Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Cytokines; Disease-Free Survival; Drug Administration Schedule; Female; Gluconates; Head and Neck Neoplasms; Humans; Immunotherapy; Indomethacin; Injections, Subcutaneous; Interferon-gamma; Interleukin-1beta; Interleukin-2; Male; Middle Aged; Neoadjuvant Therapy; Survival Rate; Tumor Necrosis Factor-alpha | 2011 |